However, entinostat plus pembrolizumab provided a clinically meaningful benefit despite not achieving the primary response rate endpoint in the expansion cohort of ENCORE 601 that included anti-PD-(L)1-experienced patients with NSCLC [151]. Here, CD274 is linked to non-small cell lung carcinoma.